Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma

PURPOSE: FKBP51, (FKBP5), is a negative regulator of Akt. Variability in FKBP5 expression level is a major factor contributing to variation in response to chemotherapeutic agents including gemcitabine, a first line treatment for pancreatic cancer. Genetic variation in FKBP5 could influence its funct...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellsworth, Katarzyna A., Eckloff, Bruce W., Li, Liang, Moon, Irene, Fridley, Brooke L., Jenkins, Gregory D., Carlson, Erin, Brisbin, Abra, Abo, Ryan, Bamlet, William, Petersen, Gloria, Wieben, Eric D., Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731355/
https://www.ncbi.nlm.nih.gov/pubmed/23936393
http://dx.doi.org/10.1371/journal.pone.0070216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731355/
https://www.ncbi.nlm.nih.gov/pubmed/23936393
http://dx.doi.org/10.1371/journal.pone.0070216

Ejemplares similares